TearClear
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12085 Research Dr, Alachua, Florida, 326...Phone Number
(352) 328-0362Website
www.tearclear.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About TearClear
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. The company's lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first in class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.Explore more
TearClear Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TearClear your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
TearClear, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at TearClear
Product Launch: Get notified when TearClear launches new products
Check out if TearClear is spiking on competitors!
Check if TearClear has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on TearClear recently announced quarterly report
Funding: Get notified immidiatlly once TearClear has new funding data
Click to see if TearClear had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at TearClear
Find 3 more new buyers
Compare Similar Companies to TearClear
Compare insights from companies similar to TearClear, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TearClear is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TearClear is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TearClear.
TearClear financials insights
Gather financial insights about TearClear, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$4.5M
2020
Series B
$22M
TearClear Tech Stack
A closer look at the technologies used by TearClear
Most Recent Scoops
Left Company
Executive Move
New Hire
Executive Move
Funding
Management Move
Executive Move
Executive Moves
TearClear News & Media
Stuart Raetzman appointed as interim CEO at TearClear
TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.TearClear Moving Toward Clinical Trials and Strengthening Leadership Team
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND meeting with the US FDA achieved in Nov. 2020, the TearClear team is now advancing the preparation of clinical trial material required for its proprietary latanoprost pivotal study in anticipation of an IND submission later this year. Today, TearClear also announces the appointment of Stuart RaetzmanTearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathway Prepared to file an IND in mid-2021 via the 505(b)(2) NDA pathwayTearClear Appoints Robert Bailey to Board of Directors
Bailey’s executive experience in the Ophthalmology industry further strengthens the organization Bailey’s executive experience in the Ophthalmology industry further strengthens the organization
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TearClear
Sign Up For FreeTo access detailed company insights
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. The company's lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first in class platform of drugs enables medication d... Read More
